Loading clinical trials...
Loading clinical trials...
With or withoutA140 + mFOLFOX6 Treat 1st Line mCRC in RAS Wide Type, Multicenter, Double-blind, Randomized, Controlled Phase III Trial
Conditions
Interventions
KL-140
Placebo
Locations
1
China
307 Hospital of PLA
Beijing, Beijing Municipality, China
Start Date
February 1, 2018
Primary Completion Date
December 1, 2020
Completion Date
December 1, 2023
Last Updated
February 8, 2018
NCT04657068
NCT06625775
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions